Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 5/20 | 0.37 |
| ▸ | MAOB | P27338 | 8/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5279069 | 0.86 | ADRB2 (0.38) | MAOBADRB2ADRB1ADRB3MAOA | |
| SCHEMBL9574255 | 0.83 | FOLH1 (0.41) | MAOBADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL11571707 | 0.82 | MEN1 (0.40) | NR1H3MAOBADRB2ADRB1ADRB3 | |
| SCHEMBL3978402 | 0.82 | ADRA1D (0.45) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL4627389 | 0.80 | ADRB2 (0.47) | ADRB2ADRB1ADRB3 | |
| SCHEMBL10464521 | 0.77 | ADRB2 (0.46) | NR1H3ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL10766081 | 0.77 | ADRB2 (0.38) | MAOBADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL10465045 | 0.76 | ADRB2 (0.42) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL10463962 | 0.76 | MRGPRX4 (0.40) | NR1H3MAOBADRB2ADRB1ADRB3 | |
| SCHEMBL11670452 | 0.76 | MEN1 (0.39) | NR1H3MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370521-B1 | FORMANILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7045658-B2 | prophylaxis and treatment of respiratory diseases; phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20040157830-A1 | Formailide derivatives as beta2-adrenoreceptor agonists | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| WO-2004039762-A1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| EP-1370521-A1 | FORMANILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002076933-A1 | FORMAILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157830-A1 | Formailide derivatives as beta2-adrenoreceptor agonists | ADRB2, ADRB1, ADRA2A | NR1H3 187/4885MAOB 788/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.